Treatment of refractory ulcerative necrobiosis lipoidica diabeticorum with infliximab: Report of a case

Archives of Dermatology

Volumn 145, Issue 4, 2009, Pages 437-439

  Li, Vincent W ^a   Hu, Stephanie W ^a   Bevona, Caroline ^c,d   Winterfield, Laura ^e   Qureshi, Abrar A ^b  

^a Department of Dermatology   (United States)

^b Dermatology Rheumatology Center

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; TRIAMCINOLONE ACETONIDE;

AGED; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; FEMALE; GRANULATION TISSUE; HUMAN; HUMAN TISSUE; INSULIN DEPENDENT DIABETES MELLITUS; LEG; NECROBIOSIS LIPOIDICA; OPPENHEIM URBACH SYNDROME; PAPULE; PRIORITY JOURNAL; SKIN BIOPSY; SKIN COLOR; SKIN DEFECT; SKIN ULCER; ULCERATIVE NECROBIOSIS LIPOIDICA DIABETICORUM; WOUND CARE; WOUND HEALING;

AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEG DERMATOSES; NECROBIOSIS LIPOIDICA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 65349182941     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2009.6     Document Type: Article

References (29)

1. Huntley AC. The cutaneous manifestations of diabetes mellitus. J Am Acad Dermatol. 1982;7(4):427-455.
2. Peyri J, Moreno A, Marcoval J. Necrobiosis lipoidica. Semin Cutan Med Surg. 2007;26(2):87-89.
3. KörberA, Dissemond J. Necrobiosis lipoidica diabeticorum. CMAJ. 2007;177(12) 1498.
4. Kalus AA, Chien AJ, Olerud JE. Diabetes mellitus and other endocrine diseases n: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, eds. Fitzpatrick's Dermatology in General Medicine. New York, NY: McGraw-Hill; 2008: 1467-1470.
5. LowittMH, Dover JS. Necrobiosis lipoidica. J Am Acad Dermatol. 1991;25(5, pt 1):735-748.
6. Boyd AS. Thiazolidinediones in dermatology. Int J Dermatol. 2007;46(6):557-563.
7. Boyd AS. Tretinoin treatment of necrobiosis lipoidica diabeticorum. Diabetes Care. 1999;22(10):1753-1754.
8. ZeichnerJA, Stern DWK, Lebwohl M. Treatment of necrobiosis lipoidica with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol. 2006;54 (3)(suppl 2):S120-S121.
9. Noz KC, Korstanje MJ, Vermeer BJ. Ulcerating necrobiosis lipoidica effectively treated with pentoxifylline. Clin Exp Dermatol. 1993;18(1):78-79.
10. Heng MC, Song MK, Heng MK. Healing of necrobiotic ulcers with antiplatelettherapy: correlation with plasma thromboxane levels. Int J Dermatol. 1989;28(3):195-197
11. Arbiser JL, MoschellaSL. Clofazimine: a review of its medical uses and mechanisms of action. J Am Acad Dermatol. 1995;32(2, pt 1):241-247.
12. Mensing H. Clofazimine: therapeutic alternative in necrobiosis lipoidica and granuloma annulare. Hautarzt. 1989;40(2):99-103.
13. Bouhanick B, Verret JL, Gouello JP, Berrut G, Marre M. Necrobiosis lipoidica: treatment by hyperbaric oxygen and local corticosteroids. Diabetes Metab. 1998; 24(2)156-159.
14. Weisz G, Ramon Y, Waisman D, Melamed Y. Treatment of necrobiosis lipoidica diabeticorum by hyperbaric oxygen. Acta Derm Venereol. 1993;73(6):447-448
15. Kreuter A, Knierim C, StuckerM, etal. Fumaric acid esters in necrobiosis lipoidica: results of a prospective non-controlled study. Br J Dermatol. 2005; 153(4):802-807.
16. KukrejaT, Petersen J. Thalidomide for the treatment of refractory necrobiosis lipoidica. Arch Dermatol. 2006;142(1):20-22.
17. Harth W, Linse R. Topical tacrolimus in granuloma annulare and necrobiosis lipoidica. Br J Dermatol. 2004;150(4):792-794.
18. Reinhard G, Lohmann F, Uerlich M, Bauer R, BieberT. Successful treatment of ulcerated necrobiosis lipoidica with mycophenolate mofetil.ActaDerm Venereol. 2000;80(4):312-313.
19. Stinco G, Parlangeli ME, De Francesco V, Frattasio A, Germino M, Patrone P. Ulcerated necrobiosis lipoidica treated with cyclosporine A. Acta Derm Venereol. 2003;83(2):151-153.
20. Stanway A, Rademaker M, Newman P. Healing of severe ulcerative necrobiosis lipoidica with cyclosporine. Australas J Dermatol. 2004;45(2):119-122.
21. De Rie MA, SommerA, Hoekzema R, Neumann HA. Treatment of necrobiosis lipoidica with topical psoralen plus ultraviolet A. Br J Dermatol. 2002;147(4):743-747.
22. Heidenheim M, Jemec GBE. Successful treatment of necrobiosis lipoidica diabeticorum with photodynamic therapy. Arch Dermatol. 2006;142(12):1548-1550.
23. DuruptF, Dalle S, DebarbieuxS, Balme B, RongerS, Thomas L. Successful treatment of necrobiosis lipoidica with antimalarial agents. Arch Dermatol. 2008 144(1)118-119.
24. Hertl MS, Haendle I, SchulerG, Hertl M. Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with tumour necrosis factor-α inhibitor, infliximab. Br J Dermatol. 2005;152(3):552-555.
25. Drosou A, Kirsner RS, Welsh E, Sullivan TP, Kerdel FA. Use of infliximab, an antitumor necrosis alpha antibody, for inflammatory dermatoses. J Cutan Med Surg. 2003;7(5):382-386.
26. Haley H, Cantrell W, Smith K. Infliximab therapy for sarcoidosis (lupus pernio) Br J Dermatol. 2004150(1)146-149.
27. Kolde G, Muche JM, Schulze P, Fischer P, Lichey J. Infliximab: a promising new treatment option for ulcerated necrobiosis lipoidica. Dermatology. 2003;206 (2)180-181.
28. Pollice PF, Rosier RN, Looney RJ, Puzas JE, SchwarzEM, O'Keefe RJ. Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes: a potential treatment for aspetic loosening of total joint components. J Bone Joint Surg Am. 2001;83(7)1057-1061.
29. Rowland TL, McHugh SM, Deighton J, Dearman RJ, Ewan PW, KimberI. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology. 1998;40 (1)11-20.